Sanofi Statistics
Total Valuation
Sanofi has a market cap or net worth of $136.42 billion. The enterprise value is $147.61 billion.
Important Dates
The last earnings date was Thursday, January 30, 2025, before market open.
| Earnings Date | Jan 30, 2025 |
| Ex-Dividend Date | May 9, 2024 |
Share Statistics
Sanofi has 1.25 billion shares outstanding. The number of shares has decreased by -0.02% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.25B |
| Shares Change (YoY) | -0.02% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.13B |
Valuation Ratios
The trailing PE ratio is 23.70 and the forward PE ratio is 12.88.
| PE Ratio | 23.70 |
| Forward PE | 12.88 |
| PS Ratio | 2.98 |
| Forward PS | 2.94 |
| PB Ratio | 1.69 |
| P/TBV Ratio | 6.63 |
| P/FCF Ratio | 22.15 |
| P/OCF Ratio | 14.51 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 12.22, with an EV/FCF ratio of 23.96.
| EV / Earnings | 25.64 |
| EV / Sales | 3.22 |
| EV / EBITDA | 12.22 |
| EV / EBIT | 16.08 |
| EV / FCF | 23.96 |
Financial Position
The company has a current ratio of 1.46, with a Debt / Equity ratio of 0.23.
| Current Ratio | 1.46 |
| Quick Ratio | 0.62 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | 1.50 |
| Debt / FCF | 3.01 |
| Interest Coverage | 13.84 |
Financial Efficiency
Return on equity (ROE) is 7.30% and return on invested capital (ROIC) is 5.88%.
| Return on Equity (ROE) | 7.30% |
| Return on Assets (ROA) | 4.28% |
| Return on Invested Capital (ROIC) | 5.88% |
| Return on Capital Employed (ROCE) | 8.56% |
| Revenue Per Employee | $553,216 |
| Profits Per Employee | $69,455 |
| Employee Count | 82,878 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 1.38 |
Taxes
In the past 12 months, Sanofi has paid $1.25 billion in taxes.
| Income Tax | 1.25B |
| Effective Tax Rate | 17.82% |
Stock Price Statistics
The stock price has increased by +16.24% in the last 52 weeks. The beta is 0.46, so Sanofi's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | +16.24% |
| 50-Day Moving Average | 50.69 |
| 200-Day Moving Average | 51.64 |
| Relative Strength Index (RSI) | 62.24 |
| Average Volume (20 Days) | 2,372,816 |
Short Selling Information
| Short Interest | 4.88M |
| Short Previous Month | 5.29M |
| Short % of Shares Out | 0.39% |
| Short % of Float | 0.43% |
| Short Ratio (days to cover) | 1.88 |
Income Statement
In the last 12 months, Sanofi had revenue of $45.85 billion and earned $5.76 billion in profits. Earnings per share was $4.60.
| Revenue | 45.85B |
| Gross Profit | 32.19B |
| Operating Income | 9.18B |
| Pretax Income | 6.07B |
| Net Income | 5.76B |
| EBITDA | 12.08B |
| EBIT | 9.18B |
| Earnings Per Share (EPS) | $4.60 |
Full Income StatementBalance Sheet
The company has $7.82 billion in cash and $18.55 billion in debt, giving a net cash position of -$10.72 billion or -$8.55 per share.
| Cash & Cash Equivalents | 7.82B |
| Total Debt | 18.55B |
| Net Cash | -10.72B |
| Net Cash Per Share | -$8.55 |
| Equity (Book Value) | 80.61B |
| Book Value Per Share | 64.01 |
| Working Capital | 13.90B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $9.40 billion and capital expenditures -$3.31 billion, giving a free cash flow of $6.16 billion.
| Operating Cash Flow | 9.40B |
| Capital Expenditures | -3.31B |
| Free Cash Flow | 6.16B |
| FCF Per Share | $4.91 |
Full Cash Flow StatementMargins
Gross margin is 70.21%, with operating and profit margins of 20.03% and 12.55%.
| Gross Margin | 70.21% |
| Operating Margin | 20.03% |
| Pretax Margin | 15.26% |
| Profit Margin | 12.55% |
| EBITDA Margin | 26.34% |
| EBIT Margin | 20.03% |
| FCF Margin | 13.43% |